tetano
Editor, Senior Moderator
Sci Rep
. 2022 Mar 29;12(1):5323.
doi: 10.1038/s41598-022-09170-4.
Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
Kazuhito Miyazaki[SUP] 1 2 [/SUP], Yukihiro Yoshimura[SUP] #[/SUP][SUP] 3 [/SUP], Nobuyuki Miyata[SUP] #[/SUP][SUP] 3 [/SUP], Hiroaki Sasaki[SUP] #[/SUP][SUP] 3 [/SUP], Aya Shiba[SUP] #[/SUP][SUP] 4 [/SUP], Masaharu Aga[SUP] #[/SUP][SUP] 4 [/SUP], Yusuke Hamakawa[SUP] #[/SUP][SUP] 4 [/SUP], Yuri Taniguchi[SUP] #[/SUP][SUP] 4 [/SUP], Yuki Misumi[SUP] #[/SUP][SUP] 4 [/SUP], Yoko Agemi[SUP] #[/SUP][SUP] 4 [/SUP], Tsuneo Shimokawa[SUP] #[/SUP][SUP] 4 [/SUP], Hiroaki Okamoto[SUP] #[/SUP][SUP] 4 [/SUP], Natsuo Tachikawa[SUP] #[/SUP][SUP] 3 [/SUP]
Affiliations
Abstract
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen's Hospital, Kanagawa, Japan. Patients with COVID-19 pneumonia treated with remdesivir were included. The onset of acute pancreatitis and increased pancreatic enzyme levels and clinical, laboratory, treatment, and outcome data were collected and analyzed. A total of 201 patients were included. Among the 201 patients treated with remdesivir, 177 recovered from COVID-19. Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in 23 of the 201 patients. The potential etiopathogenetic effects of remdesivir on increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis were ascertained by reviewing the characteristics of patients hospitalized for COVID-19 who did not receive remdesivir treatment. Only 3 of 159 patients had increased pancreatic enzyme levels of grade 3 or higher during the treatment course. Multivariate analysis indicated remdesivir administration and severe COVID-19 infection by National Institute of Health standards as independent risk factors. Acute pancreatitis and severe increases in pancreatic enzyme levels were observed among patients with COVID-19 treated with remdesivir.
. 2022 Mar 29;12(1):5323.
doi: 10.1038/s41598-022-09170-4.
Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
Kazuhito Miyazaki[SUP] 1 2 [/SUP], Yukihiro Yoshimura[SUP] #[/SUP][SUP] 3 [/SUP], Nobuyuki Miyata[SUP] #[/SUP][SUP] 3 [/SUP], Hiroaki Sasaki[SUP] #[/SUP][SUP] 3 [/SUP], Aya Shiba[SUP] #[/SUP][SUP] 4 [/SUP], Masaharu Aga[SUP] #[/SUP][SUP] 4 [/SUP], Yusuke Hamakawa[SUP] #[/SUP][SUP] 4 [/SUP], Yuri Taniguchi[SUP] #[/SUP][SUP] 4 [/SUP], Yuki Misumi[SUP] #[/SUP][SUP] 4 [/SUP], Yoko Agemi[SUP] #[/SUP][SUP] 4 [/SUP], Tsuneo Shimokawa[SUP] #[/SUP][SUP] 4 [/SUP], Hiroaki Okamoto[SUP] #[/SUP][SUP] 4 [/SUP], Natsuo Tachikawa[SUP] #[/SUP][SUP] 3 [/SUP]
Affiliations
- PMID: 35351942
- DOI: 10.1038/s41598-022-09170-4
Abstract
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen's Hospital, Kanagawa, Japan. Patients with COVID-19 pneumonia treated with remdesivir were included. The onset of acute pancreatitis and increased pancreatic enzyme levels and clinical, laboratory, treatment, and outcome data were collected and analyzed. A total of 201 patients were included. Among the 201 patients treated with remdesivir, 177 recovered from COVID-19. Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in 23 of the 201 patients. The potential etiopathogenetic effects of remdesivir on increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis were ascertained by reviewing the characteristics of patients hospitalized for COVID-19 who did not receive remdesivir treatment. Only 3 of 159 patients had increased pancreatic enzyme levels of grade 3 or higher during the treatment course. Multivariate analysis indicated remdesivir administration and severe COVID-19 infection by National Institute of Health standards as independent risk factors. Acute pancreatitis and severe increases in pancreatic enzyme levels were observed among patients with COVID-19 treated with remdesivir.